
	Juno is a clinical stage company that brings together three of the world&#39;s leading cancer centers &ndash; Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children&#39;s Research Institute &ndash; in unique partnership to advance a broad pipeline of potential curative immunotherapy treatments. With one of the largest ever Series A investments for a biotech startup, Juno will build on breakthroughs in the design of novel immunotherapies to develop two distinct and complementary platforms &ndash; chimeric antigen receptors (CARs) and T-cell receptors (TCRs). The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have potential to reduce longer-term toxicities associated with current chemotherapeutics. Juno&#39;s goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure.
